The Starpharma Holdings Ltd (ASX: SPL) share price surged 9.6% on the ASX yesterday after the company released its presentation to institutional investors at a Goldman Sachs conference in Sydney.
What was in the presentation?
Starpharma's presentation was to institutional investors at the invitation-only Goldman Sachs Tenth Annual Emerging Companies Conference in Sydney alongside 40 other ASX-listed emerging companies.
The company highlighted its $350 million market cap and status as an S&P/ASX300 Index (ASX: XKO) member with 57% institutional, 41% retail and 2% internal ownership.
The company's VivaGel and DEP Drug Delivery portfolios are underpinned by over 100 patents and the presentation demonstrated Starpharma's strong commercial pipeline across preclinical, clinical/regulatory and commercial stages of development.
In terms of financial position, Starpharma's showed a lower cash burn rate of $6.9 million in 1H19 (compared to $11.3 million in 1H18) despite ongoing losses from operations of $7.3 million in the half.
Starpharma drilled down into several key products across its portfolios including potential product launches in 2H19 and encouraging market research results across global markets.
Should you buy Starpharma's shares?
The presentation's outlook section looked at the potential for radiopharmaceuticals which is estimated to be $12 billion – $15 billion by 2030 according to a nuclear medicine world market report & directory from MEDraysintell.
Positively for the company's growth prospects, it has products across multiple markets and the potential to generate several diversified and successful revenue streams in the medium to long-term.
At $1.08 per share, the company's shares are well within its 52-week low to 52-week high range of $0.87 – $1.66 per share.
Starpharma remains a loss-making company but should it mature and capture some of the lucrative pharmaceuticals markets in the next 5-10 years, it could see its share price surge much higher than its current valuation.
For those Fools looking for something a little more niche, I'd suggest checking out this buy-rated stock that could be set to take a new-age $22 billion industry by storm.
